Protease inhibitor-based antiretroviral prophylaxis during pregnancy and the development of drug resistance

Clinical Infectious Diseases

Volumn 50, Issue 6, 2010, Pages 890-894

  Gingelmaier, Andrea ^a   Eberle, Josef ^a   Kost, Bernd P ^a   Bogner, Johannes R ^b   Hofmann, Joerg ^c   Weissenbacher, Tobias ^a   Kästner, Ralph ^a   Friese, Klaus ^a   Weizsaecker, Katharina ^c  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; INDINAVIR; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CLINICAL ARTICLE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; PROTEINASE INHIBITION; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS MUTATION; VIRUS TRANSMISSION;

ADULT; ANTI-HIV AGENTS; CHEMOPREVENTION; DRUG RESISTANCE, VIRAL; FEMALE; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MUTATION, MISSENSE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RNA, VIRAL; YOUNG ADULT;

EID: 77749251804     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/650747     Document Type: Article

References (30)

1. 1. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. European Collaborative Study. Clin Infect Dis 2005;40:458-465. (Pubitemid 40216516)
2. Warszawski J, Tubiana R, Le Chenadec J, et al. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS 2008;22:289-299.
3. Public Health Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. . Accessed 29 April 2009.
4. Eshleman SH, Mračna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-I vertical transmission (HIVNET 012). AIDS 2001; 15: 1951-1957.
5. 5. Flys T, Nissley DV, Claasen CW, et al. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis 2005; 192:24-29. (Pubitemid 40863853)
6. 6. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapinebased antiretroviral therapy. N Engl J Med 2004;351:229-240. (Pubitemid 38922817)
7. 7. Parker MM, Wade N, Lloyd RM Jr, et al. Prevalence of genotypic drug resistance among a cohort of HIV-infected newborns. J Acquir Immune Defic Syndr 2003;32:292-297. (Pubitemid 36331701)
8. Coffie PA, Ekouevi DK, Chaix ML, et al. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006. Clin Infect Dis 2008;46: 611-621.
9. 9. Lyons FE, Coughlan S, Byrne CM, Hopkins SM, Hall WW, Mulcahy FM. Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy. AIDS 2005; 19:63-67. (Pubitemid 40111019)
10. 10. Buchholz B, Beichcrt M., Marcus U, et al. German-Austrian recommendations for HIV-therapy in pregnancy and in HIV-exposed newborn-update 2005. Eur J Med Res 2006; 11:359-376. (Pubitemid 44575696)
11. Wolff D, Gerritzen A. Comparison of the Roche COBAS Amplicor Monitor, Roche COBAS Ampliprep/COBAS Taqman and Abbott RealTime Test assays for quantification of hepatitis C virus and HIV RNA. Clin Chem Lab Med 2007;45:917-922.
12. HIV-GRADE. http://www.hiv-grade.de/cms/grade/grade-tool.html Accessed 20 April 2009.
13. HIV french resistance. HIV-I genotypic drug resistance interpretations algorithms, http://www.hivfrenchrcsistancc.org. Accessed 20 April 2009.
14. Laboratory for clinical and evolutionary virology. The Rega Algorithms. http://www.rega.kuleuven.be/cev/index.php?id = 30. Accessed 20 April 2009.
15. Stanford University. HIV drug resistance database. http://hivdb?stanford. edu/.Accessed 20 April 2009.
16. Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009; 4:e4724.
17. Universität Erlangen-Nürnberg. Geno2pheno. http://www. geno2pheno.org/cgi-bin/geno2pheno.pl. Accessed 20 April 2009.
18. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994; 22:4673-4680.
19. 19. Duran AS, Losso MH, Salomon H, et al. Drug resistance among HIVinfected pregnant women receiving antiretrovirals for prophylaxis. AIDS 2007;21:199-205. (Pubitemid 46036928)
20. Kakehasi FM, Tupinambas U, Cleto S, et al. Persistence of genotypic resistance to nelfinavir among women exposed to prophylactic antiretroviral therapy during pregnancy. AIDS Res Hum Retroviruses 2007; 23: 1515-1520.
21. Lichterfeld M, Wohrmann A, Schmeisser N, et al. Superior virological efficacy of ritonavir-boosted protease inhibitor regimens compared to single protease inhibitor therapy. Eur J Med Res 2003; 8:56-60.
22. 22. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002;346:2039-2046. (Pubitemid 34680595)
23. Bartlett JA, Fath MJ, Demasi R, et al. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS 2006;20:2051-2064.
24. 24. Zorrilla CD, Van Dyke R, Bardeguez A, et al. Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants. Antimicrob Agents Chemother 2007;51:2208-2210. (Pubitemid 46903119)
25. Welles SL, Bauer GR, LaRussa PS, Colgrove RC, Pitt J. Time trends for HIV-1 antiretroviral resistance among antiretroviral-experienced and naive pregnant women in New York City during 1991 to early 2001. J Acquir Immune Defic Syndr 2007;44:329-335.
26. 26. Schmitz T, Kleinkauf N, Klempa B, Ringe H, Varnholt V, GroschWorner I. Transmission of human immunodeficiency virus type 1 nevirapine resistance mutation K103N from a treatment-naive mother to her child. Pediatr Infect Dis J 2006; 25:275-276. (Pubitemid 43379076)
27. 27. Palmer S, Kearney M, Maldarelli F, et al. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatmentexperienced patients are missed by standard genotype analysis. J Clin Microbiol 2005;43:406-413. (Pubitemid 40096331)
28. Eshleman SH, Guay LA, Mwatha A, et al. Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after singledose NVP prophylaxis: HIVNET 012. AIDS Res Hum Retroviruses 2004; 20:595-599.
29. 29. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007; 356:135-147. (Pubitemid 46089674)
30. 30. Thome C, Patel D, Newell ML. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS 2004; 18:2337-2339. (Pubitemid 39620231)